Estrategias Combinadas en Inmunoterapia Traslacional
ITC
University of Chicago
Chicago, Estados UnidosPublicacións en colaboración con investigadores/as de University of Chicago (7)
2024
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
2016
-
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920
-
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma
Clinical Cancer Research
-
Perspectives in immunotherapy: Meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015
Journal for ImmunoTherapy of Cancer, Vol. 4, Núm. 1
2014
-
Classification of current anticancer immunotherapies
Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508
2012
2010
-
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies
Seminars in Oncology, Vol. 37, Núm. 5, pp. 508-516